We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Guardian Pharmacy Services to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
Key Takeaways
GRDN is set to report Q1 2026 results on May 6, with revenues expected at $329.7M and EPS at 24 cents.
Guardian Pharmacy Services saw growth driven by new residents, script gains and acquisitions.
GRDN may face pressure from IRA-related pricing despite rising vaccine prescription volumes.
Guardian Pharmacy Services (GRDN - Free Report) is scheduled to report first-quarter 2026 results on May 6, after market close. We expect investors to focus on GRDN’s sales performance when the company reports quarterly results.
The Zacks Consensus Estimate for first-quarter revenues is pegged at $329.7 million, while the same for earnings per share is pegged at 24 cents.
Year to date, shares of Guardian Pharmacy Services have rallied 23.3% against the industry’s 2.5% decline.
Image Source: Zacks Investment Research
Let’s see how things might have shaped up for GRDN in the soon-to-be-reported quarter.
Factors Likely to Influence GRDN’s Q1 Results
Guardian Pharmacy Services is a U.S.-based provider of pharmacy services to long-term care and assisted living facilities. The company delivered a strong performance in the fourth quarter of 2025 with organic growth driven by new resident additions, script growth and higher acuity. Acquisitions also complemented organic growth. The positive trend is expected to have continued in the first quarter. Vaccine prescription volumes are also expected to have risen in the first quarter due to continued growth and improving execution of the vaccine program. However, the new IRA-related pricing impact may have hurt revenues to an extent in the first quarter.
Earnings Surprise History
Guardian Pharmacy Services has a mixed history of earnings surprises. The company beat earnings estimates in three of the trailing four quarters, while missing the same on the remaining occasion, delivering an average surprise of 10.30%. In the last reported quarter, GRDN delivered an earnings surprise of 37.04%.
Guardian Pharmacy Services, Inc. Price and EPS Surprise
Our proven model does not conclusively predict an earnings beat for GRDN this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Guardian Pharmacy Services has an Earnings ESP of 0.00%.
Zacks Rank: Guardian Pharmacy Services currently sports a Zacks Rank #1.
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +7.81% and carries a Zacks Rank #3 at present.
Shares of ANIP have risen 0.7% year to date. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 22.21%.
United Therapeutics (UTHR - Free Report) has an Earnings ESP of +1.67% and a Zacks Rank #3 at present.
Shares of UTHR have risen 17.3% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 4.29%. United Therapeutics is scheduled to report first-quarter results on May 6.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +75.24% and a Zacks Rank #3 at present.
Shares of ACAD have plunged 15.9% year to date. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 35.83%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Guardian Pharmacy Services to Report Q1 Earnings: What's in the Cards?
Key Takeaways
Guardian Pharmacy Services (GRDN - Free Report) is scheduled to report first-quarter 2026 results on May 6, after market close. We expect investors to focus on GRDN’s sales performance when the company reports quarterly results.
The Zacks Consensus Estimate for first-quarter revenues is pegged at $329.7 million, while the same for earnings per share is pegged at 24 cents.
Year to date, shares of Guardian Pharmacy Services have rallied 23.3% against the industry’s 2.5% decline.
Image Source: Zacks Investment Research
Let’s see how things might have shaped up for GRDN in the soon-to-be-reported quarter.
Factors Likely to Influence GRDN’s Q1 Results
Guardian Pharmacy Services is a U.S.-based provider of pharmacy services to long-term care and assisted living facilities. The company delivered a strong performance in the fourth quarter of 2025 with organic growth driven by new resident additions, script growth and higher acuity. Acquisitions also complemented organic growth. The positive trend is expected to have continued in the first quarter. Vaccine prescription volumes are also expected to have risen in the first quarter due to continued growth and improving execution of the vaccine program. However, the new IRA-related pricing impact may have hurt revenues to an extent in the first quarter.
Earnings Surprise History
Guardian Pharmacy Services has a mixed history of earnings surprises. The company beat earnings estimates in three of the trailing four quarters, while missing the same on the remaining occasion, delivering an average surprise of 10.30%. In the last reported quarter, GRDN delivered an earnings surprise of 37.04%.
Guardian Pharmacy Services, Inc. Price and EPS Surprise
Guardian Pharmacy Services, Inc. price-eps-surprise | Guardian Pharmacy Services, Inc. Quote
Earnings Whispers for GRDN
Our proven model does not conclusively predict an earnings beat for GRDN this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Guardian Pharmacy Services has an Earnings ESP of 0.00%.
Zacks Rank: Guardian Pharmacy Services currently sports a Zacks Rank #1.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +7.81% and carries a Zacks Rank #3 at present.
Shares of ANIP have risen 0.7% year to date. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 22.21%.
United Therapeutics (UTHR - Free Report) has an Earnings ESP of +1.67% and a Zacks Rank #3 at present.
Shares of UTHR have risen 17.3% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 4.29%. United Therapeutics is scheduled to report first-quarter results on May 6.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +75.24% and a Zacks Rank #3 at present.
Shares of ACAD have plunged 15.9% year to date. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 35.83%.